SCOTUS Mifepristone Ruling Leaves Employers in Coverage Quandary
In the article “Supreme Court’s Mifepristone Ruling Leaves Coverage Quandary,” Bloomberg Law covers the U.S. Supreme Court’s decision to dismiss a lawsuit challenging the approval of the abortion drug mifepristone, which has left many questions unanswered for employers, health plans, medical providers and pharmacies regarding compliance and coverage of abortion drugs. This decision, while temporarily clearing the way for patient access to mifepristone, does not address the underlying complexities tied to the decades-long battle over abortion rights in the United States.
Attorneys highlight the intricate web of state regulations that continues to create uncertainty. These state laws not only create a patchwork of regulatory environments but also potentially place employers in a difficult position regarding drug coverage decisions for their employees. Sheppard Mullin Healthcare partner Amanda Zablocki commented, “If you’re in a state where there’s a lot of politicizing around the border, or where there’s very restrictive laws, then yes, there’s of course hesitancy. I think there’s a lot of conflicting laws and regulations that providers are grappling with.”
The prospect of future court cases that loom further complicate the issue of abortion drug access and coverage in the U.S.
Click here to read the full article. (A subscription is required)